metricas
covid
Buscar en
Clínica e Investigación en Ginecología y Obstetricia
Toda la web
Inicio Clínica e Investigación en Ginecología y Obstetricia Carcinoma primario de trompa de falopio. presentación de 9 casos
Información de la revista
Vol. 31. Núm. 7.
Páginas 237-243 (enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 31. Núm. 7.
Páginas 237-243 (enero 2004)
Acceso a texto completo
Carcinoma primario de trompa de falopio. presentación de 9 casos
Visitas
4036
F. Puig, R. Crespo, V. Echavarren, J.M. Castillo, R. Lanzon
Servicio de Ginecología.Hospital Materno-Infantil.Hospital Universitario Miguel Servet.Zaragoza.España.
Este artículo ha recibido
Información del artículo
Resumen

Objetivo:El propósito de este estudio es presentar la experiencia del Servicio de Ginecología del Hospital Universitario Miguel Servet de Zaragoza con respecto al carcinoma primario de trompa de Falopio.

Material y métodos:Presentamos los datos correspondientes a 9 pacientes con carcinoma primario de trompa de Falopio,tratadas y posteriormente controladas en nuestro hospital entre el 1 de enero de 1995 y el 30 de junio de 2003.

Resultados:Distribuidas por estadios,2 pacientes se etiquetaron en estadio IA; 2,estadio IC; 2,estadio IIIA; 2,estadio IIIC,y 1 estadio IV. En todos los casos,el tratamiento inicial fue quirúrgico y, posteriormente, 7 pacientes recibieron quimioterapia adyuvante; ninguna recibió radioterapia. Preoperatoriamente,sólo se sospechó en un caso y en todas las pacientes el tipo histológico fue adenocarcinoma papilar seroso. El seguimiento ha oscilado entre 9 y 95 meses,con una media de 52; 2 pacientes han fallecido por la enfermedad a los 12 y 42 meses de seguimiento,2 pacientes están vivas pero con presencia de enfermedad y 5 están vivas y libres de enfermedad.

Conclusiones:El carcinoma de trompa de Falopio es un tumor de difícil diagnóstico preoperatorio, que presenta como síntomas más habituales la hemorragia vaginal anormal y el dolor pélvico. Su tratamiento es fundamentalmente quirúrgico y debe seguir pautas similares a las que aplicamos en el carcinoma de ovario.

Abstract

Objective:The aim of the current study is to review the experience of the Gynaecology Department of Zaragoza’s Miguel Servet University Hospital with primary cancer of the fallopian tube.

Materials and methods:We review 9 cases of primary tubal carcinoma treated and followed up in our hospital between the first of January 1995 and the thirtieth of June 2003.

Results:According to the FIGO staging system 2 patients were stage IA, 2 stage IC, 2 stage IIIA, 2 stage IIIC and 1 stage IV. All patients underwent initial surgery and 7 received adjuvant chemotherapy; no one received radiotherapy. There was preoperative suspicion in only one case, and in all patients the histological type was serous papillary adenocarcinoma. The follow up period ranged from 9 to 95 months, with an average of 52 months. Two patients died of the disease after 12 and 42 months of follow up, 2 patients are alive with persistent disease and 5 are alive with no evidence of disease.

Conclusions:Fallopian tube carcinoma is a tumor which is difficult to diagnose preoperatively, whose most common presenting symptoms are abnormal vaginal bleeding and pelvic pain. Treatment is mainly surgical, and following the same principles as in ovarian carcinoma is recommended.

El Texto completo está disponible en PDF
Bibliografía
[1.]
AJ. Nordin.
Primary carcinoma of the fallopian tube: a 20- year literature review.
Obstet Gynecol Surv, 49 (1994), pp. 349-361
[2.]
I Alvarado-Cabrero, RH Young, EC Vamvakas, RE. Scully.
Carcinoma of the fallopian tube: a clinicophatological study of 105 cases with observations on staging and prognostic factors.
Gynecol Oncol, 72 (1999), pp. 367-379
[3.]
G Rauthe, HW Vahrson, E. Burkhardt.
Primary cancer of the fallopian tube: treatment and results of 37 cases.
Eur J Gynaecol Oncol, 19 (1998), pp. 356-362
[4.]
A Rosen, M Klein, M Lahousen, AH Graf, A Rainer, N Vavra.
for the Austrian Cooperative Study Group for Fallopian TubeCarcinoma. Primary carcinoma of the fallopian tube; a retrospective analysis of 115 patients.
Br J Cancer, 68 (1993), pp. 605-609
[5.]
A. Sedlis.
Primary carcinoma of the fallopian tube.
ObstetGynecol Surv, 16 (1961), pp. 209-226
[6.]
KA Rosenblatt, NS Weis, SM. Schwartz.
Incidence of malignant fallopian tube tumors.
Gynecol Oncol, 35 (1989), pp. 236-239
[7.]
M Baekelandt, M Kockx, F Wesling, J. Gerris.
Primary adenocarcinoma of the fallopian tube: review of the literature.
Int J Gynecol Cancer, 3 (1993), pp. 65-71
[8.]
AH. Tulusan.
Cancer of the fallopian tube.
Surgical gynecologic oncology.Stuttgart, pp. 417-421
[9.]
A Kurjak, S Kupesic, M Ilijas, V Sparac, D. Kosuta.
Preoperative diagnosis of primary fallopian tube carcinoma.
Gynecol Oncol, 68 (1998), pp. 29-34
[10.]
S Pecorelli, F Odicino, P Maisonnave, W Creasman, J Shepherd, M Sideri, et al.
Carcinoma of the fallopian tube.
J Epidemiol Biostat, 3 (1998), pp. 63-74
[11.]
EH McMurray, AJ Jacobs, CA Pérez, HM Camel, MS Kao, A. Galakatos.
Carcinoma of the fallopian tube: management and sites of failure.
Cancer, 58 (1986), pp. 2070-2075
[12.]
CY Hu, ML Taymor, AT. Hertig.
Primary carcinoma of the fallopian tube.
Am J Obstet Gynecol, 59 (1950), pp. 58-60
[13.]
M. Yoonessi.
Carcinoma of the fallopian tube.
Obstet Gynecol Surv, 34 (1979), pp. 257-270
[14.]
W. Latzko.
Linkseitiges tubenkarzinom rechteitige karzinomatose tuboovarial cyste.
Zentralbl Gynak, 40 (1916), pp. 599
[15.]
RH Young, RE. Scully.
Pathology of tumors of fallopian tube and broad ligament.
Gynecologic oncology: fundamental principles and clinical practice, pp. 843-852
[16.]
JL Benedet, DM. Miller.
Tumors of fallopian tube: clinical features, staging and management.
Gynecologic oncology: fundamental principles and clinical practice, 2nd, pp. 853-860
[17.]
L Borghi, MR Ballotta, E Bianchini, B Garavello, A Bononi, RM. Fortini.
Primary carcinoma of fallopian tube: experience of six cases.
Eur J Obstet Gynecol Reprod Biol, 57 (1994), pp. 161-166
[18.]
GL Eddy, LJ Copeland, DM Gershenson, EN Atkinson, JT Wharton, FN. Rutledge.
Fallopian tube carcinoma.
Obstet Gynecol, 64 (1984), pp. 546-552
[19.]
A King, IM Seraj, T Thrasher, J Slater, RJ. Wagner.
Fallopian tube carcinoma: a clinicopathological study of 17 cases.
Gynecol Oncol, 33 (1989), pp. 351-355
[20.]
WA III Peters, WA Andersen, MP Hopkins, NB Kumar, GW. Morley.
Prognostic features of carcinoma of the fallopian tube.
Obstet Gynaecol, 71 (1988), pp. 757-762
[21.]
M Baekelandt, M Kockx, F Wesling, J. Gerris.
Primary adenocarcinoma of the fallopian tube: review of the literature.
Int J Gynecol Cancer, 3 (1993), pp. 65-71
[22.]
KS Raju, GH Barker, E. Wiltshaw.
Primary carcinoma of the fallopian tube: report of 22 cases.
Br J Obstet Gynaecol, 88 (1981), pp. 1124-1129
[23.]
AC Hellstrom, C Silversward, B Nilsson, F. Petterson.
Carcinoma of the fallopian tube: a clinical and histopathologic review. The radiumhemmet series.
Int J Gynecol Cancer, 4 (1994), pp. 408-413
[24.]
JM Niloff, TL Klug, E Schaetzl, VR Zurawski, RC Knapp, RC. Bast.
Elevation of serum CA-125 in carcinomas of the fallopian tube, endometrium and endocervix.
Am J Obstet Gynecol, 148 (1984), pp. 1057-1058
[25.]
AC Rosen, M Klein, HR Rosen, AH Graf, M Lahousen, A Reiner, et al.
Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma.
Arch Gynecol Obstet, 255 (1994), pp. 65-68
[26.]
L Puls, D Davey, P DePriest, HH Gallion, JR Jr Van Nagell, JE. Hunter.
Immunohistochemical staining for CA-125 in fallopian tube carcinoma.
Gynecol Oncol, 48 (1993), pp. 360-363
[27.]
A Makar, G Kristensen, J Nesland, OP Bormer, CG. Tropé.
Serum CA-125 as a tumor marker and the expresion of cerbB- 2 oncogene in tubal malignancies.
Int J Gynecol Cancer, 3 (1993), pp. 116-121
[28.]
S Makhija, N Howden, J Edwards, D Kelley, DW Townsend, CC. Meltzer.
Positron emission tomographycomputed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review.
Gynecol Oncol, 85 (2002), pp. 53-58
[29.]
Practice guidelines: fallopian tube cancer. Society of gynecologic oncologists. Clinical practice guidelines. Oncology 1998;12:287-8
[30.]
M Markman, A Kennedy, K Webster, G Peterson, B Kulp, J. Belinson.
Combination chemotherapy with carboplati and docetaxel in the treatment of cancers of the ovary, fallopian tube and primary carcinoma of the peritoneum.
J ClinOncol, 19 (2001), pp. 1901-1905
[31.]
G Rauthe, HW Vahrson, E. Burkhardt.
Primary cancer of the fallopian tube: treatment and results of 37 cases.
Eur J Gynaecol Oncol, 19 (1998), pp. 356-362
[32.]
HM Phelps, KE. Chapman.
Role of radiation therapy in treatment of primary carcinoma of the uterine tube.
Obstet Gynecol, 43 (1974), pp. 669-673
[33.]
Z Kojs, K Urbanski, M Reinfuss, K Karolewski, M Klimek, J. Puderlek.
Whole abdominal external beam radiation in the treatment of primary carcinoma of the fallopian tube.
Gynecol Oncol, 65 (1997), pp. 473-477
[34.]
AC Rosen, M Klein, E Hafner, M Lahousen, AH Graf, A. Reiner.
Management and prognosis of primary fallopian tube carcinoma.
Gynecol Obstet Invest, 47 (1999), pp. 45-51
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos